FindTrial
Sign In

A placebo-controlled study for SPM962 in early Parkinson's disease patients

A placebo-controlled study for SPM962 in early Parkinson's disease patients

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220443
Enrollment
Unknown
Registered
2007-09-18
Start date
2007-09-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

investigational material(s) Generic name etc : SPM962 INN of investigational material : Therapeutic category code : 116 Antiperkinsonism agents Dosage and Administration for Investigational material

Sponsors

Otsuka Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Subject is diagnosed as having Parkinson's disease 2. Subject is 30 and over, and less than 80 years of age at the time of informed consent. 3. Subject is diagnosed as modified Hoehn & Yahr stage I - III. 4. Subject's total UPDRS Part II sum score and Part III sum score is 10 and over at screening test.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy/safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026